Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

OB GYN new masthead 1

OB/GYN Clinical Alert – March 1, 2024

March 1, 2024

View Archives Issues

  • Mifepristone as a Treatment Option for Adenomyosis

    This multicenter, placebo-controlled, double-blind randomized clinical trial was conducted in 10 hospitals in China and enrolled 134 patients with diagnosed adenomyosis to evaluate mifepristone as an effective treatment for adenomyosis pain symptoms. Among the intervention group, 98.1% had total remission of adenomyosis pain symptoms as well as improved secondary outcomes with no serious adverse events. Mifepristone is promising for treating pain from adenomyosis.

  • How Does the Genitourinary Syndrome of Menopause Affect Patients?

    This analysis of baseline questionnaire responses from 302 individuals enrolled in the MsFLASH Vaginal Health Trial demonstrated that the most commonly reported symptoms were vaginal dryness (94%), pain with vaginal penetration (84%), vulvovaginal pain and soreness (76%), and vulvovaginal irritation (73%). The symptom most often rated severe was pain with vaginal penetration (40%).

  • Zuranolone Therapy for Depression in the Postpartum Period

    Zuranolone was well tolerated and resulted in substantial improvement of depressive symptoms in the postpartum period, suggesting that it may be a promising new oral therapy for postpartum depression.

  • Imported Gestational Malaria

    Pregnant women can develop malaria in non-endemic areas, even when they are far removed from malaria exposure both geographically and temporally.